Insmed's CEO keeps a newspaper story from 2014 in his office. The headline: “Insmed joins the biotech trash heap.” Now, he hopes the company can be a $100 billion biotech.

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...

Alphabet’s Calico is inking a deal worth up to $571 million biobucks for rights to Mabwell's IL-11-targeting mAb for age-related diseases.

Meanwhile, biotech veteran Jean-Paul Kress, M.D. has stepped in as CEO and Chairman of the company, replacing Dr. Robert Ang, who will stay on as a strategic advisor through October.

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

The open benchmark competition will evaluate the ability of AI-powered virtual cell models to generalize to new cell contexts for therapeutic applications.